BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/883f56/novel_antibodies_a) has announced the addition of the "Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects" report to their offering. Novel (…)
[Read article]
[Source: Business Wire]
DURHAM, NC, and LIEGE, BELGIUM - August 26, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today its 2010 half-year results and its new strategy. Highlights: Strategic/Commercial: Cervical (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e9e8b4/educating_the_mark) has announced the addition of the "Educating the Market: Creating Value Through Support of Continuing Medical Education 2010" report to their offering. Educating (…)
[Read article]
[Source: Business Wire]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection. ZymoGenetics is investigating PEG-Interferon lambda in (…)
[Read article]
[Source: Business Wire]
The 14th International Congress of Parkinson's Disease and Movement Disorders, held in Buenos Aires, included topics covering new therapeutic developments in the field of Parkinson's disease and other movement disorders. This conference report highlights selected presentations (…)
[Read article]
[Source: NCBI PubMed]
LONDON, ENGLAND, 19 August 2010 Summary of unaudited results for the six months ended 30 June 2010 H1 2010 H1 2009 £m £m Results Revenue 29.3 25.5 Research and development expenses (10.0) (10.3) Operating profit 8.6 5.4 Net profit/(loss) after tax (post exceptional) 0.9 (6.1) (…)
[Read article]
[Source: BioSpace]
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 83 percent of surveyed physicians are familiar with Merck Serono/EMD Serono's oral cladribine and Novartis/Mitsubishi Tanabe's (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a3c36b/commercial_insight) has announced the addition of the "Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal the Start of a New Era" report to their offering. (…)
[Read article]
[Source: Business Wire]
Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). The application also has been granted a Priority Review designation (…)
[Read article]
[Source: Medical News Today]
Geneva, Switzerland, 11 August 2010: PregLem, the Swiss specialty biopharmaceutical company focused on women s reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor (JNK-I AS602801) from (…)
[Read article]
[Source: BioSpace]
BETHESDA, Md.-(BUSINESS WIRE)-Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the Canaccord Genuity 30th (…)
[Read article]
[Source: Business Wire]
LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX) has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per share, from investment funds for which Perry Corp. or an affiliate acts as investment advisor and/or general partner at $0.90 (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced that the United States Department of Justice has closed its investigation of the proposed acquisition of (…)
[Read article]
[Source: Business Wire]
BETHESDA, Md.-(BUSINESS WIRE)-Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months (…)
[Read article]
[Source: Business Wire]
LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results for the three- and six-month periods ended June 30, 2010. Key financial results for the quarter and subsequent events include: Our progesterone business grew nicely (…)
[Read article]
[Source: Business Wire]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, will present at the Canaccord Annual Growth Conference in Boston on Tuesday, August 10, 2010 at 8:30 a.m. Eastern Time. A live (…)
[Read article]
[Source: Business Wire]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company s net loss declined to $3.8 million, or $0.04 per share, a $23.2 million (…)
[Read article]
[Source: Business Wire]
NOVATO, Calif., Aug. 2 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 (…)
[Read article]
[Source: BioSpace]
Novato, Calif., August 2, 2010 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced financial results for the second quarter of 2010. GAAP net loss was $0.5 million ($0.01 per diluted share) for the second quarter of 2010, compared to GAAP net income of $1.3 million (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c22923/medical_laboratori) has announced the addition of the "Medical Laboratories Industry in Argentina" report to their offering. The following report shows a sectoral diagnosis which (…)
[Read article]
[Source: Business Wire]
BETHESDA, Md.-(BUSINESS WIRE)-Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review (…)
[Read article]
[Source: Business Wire]
LYON, France-(BUSINESS WIRE)-Flamel Technologies (Nasdaq:FLML) today announced three new partnership agreements and its financial results for the second quarter of 2010. Highlights included: In addition, we believe that the applicability of the Medusa platform in creating (…)
[Read article]
[Source: Business Wire]
Horizon Pharma, Inc. announced the results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) Phase 3 European registration study of LODOTRA, a programmed release formulation of low-dose prednisone, which (…)
[Read article]
[Source: Medical News Today]
MADISON, Wis. & LIEGE, Belgium-(BUSINESS WIRE)-Exact Sciences Corp. (Nasdaq: EXAS) and OncoMethylome Sciences S.A. (Brussels: ONCOB) today announced that they have entered into a license agreement under which Exact Sciences has obtained exclusive, worldwide rights to up to (…)
[Read article]
[Source: Business Wire]
The current genotoxicity tests of the standard in vitro battery, especially those using mammalian cells, are limited by their low specificity and highlight the importance of new in vitro tools. This study aimed to evaluate the suitability of HepG2 cells for assaying mutagens (…)
[Read article]
[Source: NCBI PubMed]
Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals and cannot be determined before the final pathologic evaluation. The (…)
[Read article]
[Source: NCBI PubMed]
Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals and cannot be determined before the final pathologic evaluation. The (…)
[Read article]
[Source: NCBI PubMed]
Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals and cannot be determined before the final pathologic evaluation. The (…)
[Read article]
[Source: NCBI PubMed]
LONDON-(BUSINESS WIRE)-Market Publishers Ltd announces that new market research reports on Healthcare Equipment & Services are available in its catalogue. Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of (…)
[Read article]
[Source: Business Wire]
TOKYO-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate at CDISC Interchange Japan 2010, July 20-23 at the Toshi Center Hotel in Tokyo. Doing More with SDTM Safety Signal (…)
[Read article]
[Source: Business Wire]
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) among the surveyed oral emerging therapies for the (…)
[Read article]
[Source: Medical News Today]
BILLERICA, Mass. & DARMSTADT, Germany-(BUSINESS WIRE)-Merck KGaA*, a global pharmaceutical and chemical company, today announced the successful completion of its acquisition of Millipore Corporation (formerly NYSE: MIL), a leading Life Science company based in Billerica, (…)
[Read article]
[Source: Business Wire]
New York, NY July 14, 2010 New and improved multiple sclerosis (MS) drugs satisfying key unmet needs of oral administration and increased efficacy suggest a paradigm shift in MS therapy; ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cc5ca4/pharmaceutical_ind) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Industry Dynamics 2010: Licensing Opportunities: Rheumatology" to their (…)
[Read article]
[Source: Business Wire]
LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that as of July 8, 2010, its Board of Directors has appointed G. Frederick Wilkinson, Executive Vice President, Global Brands, of Watson Pharmaceuticals, Inc. (NYSE: WPI), as a (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f5fd68/acute_lymphocytic) has announced the addition of Decision Resources, Inc.'s new report "Acute Lymphocytic Leukemia - Unmet Needs in Adult and Pediatric Populations Drive Recent (…)
[Read article]
[Source: Business Wire]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that it will report second quarter financial results on Tuesday, August 3, 2010 after market close. Following the announcement, members of the company s senior management will discuss the results and (…)
[Read article]
[Source: Business Wire]
Micromet, Inc. (Nasdaq: MITI) announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients (…)
[Read article]
[Source: Medical News Today]
PARIS & NEW YORK-(BUSINESS WIRE)-Advised by Bionest Partners Finance Poxel raises 16 million Euros through a prestigious syndicate led by Edmond de Rothschild Investment Partners. Bionest Partners Finance, a provider of advisory and management services to Life Sciences (…)
[Read article]
[Source: Business Wire]
LYON, FRANCE-(Marketwire - July 08, 2010) - Poxel S.A. / Poxel Raises EUR16 million in a Series A Financing to Accelerate Pipeline Development processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Lyon, France, July 8, (…)
[Read article]
[Source: BioSpace]
LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX - News) announced today that it has closed the sale of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. (NYSE: WPI - News) (the Watson (…)
[Read article]
[Source: BioSpace]